Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
10 11월 2020 - 6:12AM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for population sequencing and cancer, today announced that the
company will participate in the Society for Immunotherapy of Cancer
(SITC) Annual Meeting online, November 11-14, including poster
presentations on November 11th – 13th.
The company will showcase ImmunoID NeXT™, the first platform to
enable comprehensive analysis of both a tumor and its immune
microenvironment from a single sample. ImmunoID NeXT™ can be used
to investigate the key tumor and immune-related areas of cancer
biology, consolidating multiple oncology biomarker assays into one
and maximizing the biological information that can be generated
from a precious tumor specimen.
Following is a list of abstracts that will be presented at the
meeting.
Scientific Poster Presentations
Poster Number &
Category
Title & Presenter
Day & Time
29
Biomarkers, Immune Monitoring, and Novel
Technologies
Profiling Tumor Circulating Cell-Free
DNA with an Enhanced Whole-Exome to Enable Sensitive Assessment of
Somatic Mutations
Presenter: Simo V. Zhang, PhD
NOV 11 | 5:15 – 5:45 PM EST and
NOV 13 | 4:40 – 5:10 PM EST
57
Biomarkers, Immune Monitoring, and Novel
Technologies
Precision neoantigen discovery using
novel algorithms and expanded HLA-ligandome datasets
Presenter: Dattatreya Mellacheruvu,
PhD
NOV 11 | 5:15 – 5:45 PM EST and
NOV 13 | 4:40 – 5:10 PM EST
67
Biomarkers, Immune Monitoring, and Novel
Technologies
B-cell receptor heavy chain repertoire
profiling using an augmented transcriptome
Presenter: Eric Levy, Ph.D.
NOV 11 | 5:15 – 5:45 PM EST and
NOV 13 | 4:40 – 5:10 PM EST
73
Biomarkers, Immune Monitoring, and Novel
Technologies
Orthogonally and functionally validated
algorithm for detecting HLA loss of heterozygosity
Presenter: Rachel M. Pyke, PhD
NOV 11 | 5:15 – 5:45 PM EST and
NOV 13 | 4:40 – 5:10 PM EST
Following are details of an industry-sponsored symposium which
will be presented at the meeting.
Industry Sponsor Symposium
Presentation Category
Title & Presenter
Day & Time
Sponsored Symposia
Maximizing immunotherapy biomarker
discovery with a multidimensional tumor immunogenomics
platform
Presenter: Erin N. Newburn, PhD
NOV 12 | 12:30 – 12:50 PM EST
Personalis will also be exhibiting during the online conference.
Representatives will be available to answer questions about the
company’s cancer immunogenomics services.
About Personalis, Inc.
Personalis, Inc. is a leader in population sequencing and cancer
genomics, with a focus on data, scale, efficiency and quality.
Personalis operates one of the largest sequencing operations
globally and is currently the sole sequencing provider to the U.S.
Department of Veterans Affairs Million Veteran Program (VA MVP). In
oncology, Personalis is transforming the development of
next-generation therapies by providing more comprehensive molecular
data about each patient’s cancer and immune response. The
Personalis® ImmunoID NeXT Platform® is designed to adapt to the
complex and evolving understanding of cancer, providing its
biopharmaceutical customers with information on all of the
approximately 20,000 human genes, together with the immune system,
from a single tissue sample. The Personalis Clinical Laboratory is
GxP-aligned as well as CLIA’88-certified and CAP-accredited. For
more information, please visit www.personalis.com and follow
Personalis on Twitter (@PersonalisInc).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201109006091/en/
Investor Relations Contact: Caroline Corner
investors@personalis.com 415-202-5678
Media Contact: Jennifer Havlek pr@personalis.com
www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024